Welcome to our dedicated page for Materialise news (Ticker: MTLS), a resource for investors and traders seeking the latest updates and insights on Materialise stock.
Materialise NV (MTLS) is a global leader in 3D printing solutions and additive manufacturing software, serving healthcare, automotive, and industrial sectors since 1990. This page aggregates official announcements and verified news about the company’s medical innovations, software developments, and manufacturing advancements.
Investors and industry professionals will find timely updates on quarterly earnings, strategic partnerships, and technology breakthroughs. Our curated collection includes regulatory filings, product launch details, and market expansion news – all essential for understanding Materialise’s position in the evolving digital manufacturing landscape.
Key updates cover developments across Materialise’s three core segments: medical applications improving patient care through 3D-printed implants, software solutions optimizing production workflows, and manufacturing services enabling rapid prototyping. Bookmark this page to monitor how the company addresses challenges in sustainable production and customized healthcare solutions.
Materialise NV (NASDAQ:MTLS) reported robust financial results for Q1 2023, with total revenue increasing 24.4% to 65,886 kEUR, compared to 52,961 kEUR in Q1 2022. Adjusted EBITDA significantly rose 89% to 10,310 kEUR, reflecting strong performance across its segments. The company achieved a net profit of 3,715 kEUR, a substantial increase from 127 kEUR in the previous year. Revenue from Materialise Medical surged 32.5% to 24,317 kEUR, while Materialise Manufacturing saw a growth of 25.2%. Despite rising operational expenses by 8.7%, gross profit grew to 36,837 kEUR, reflecting a gross margin of 55.9%. Looking ahead, the company raised its 2023 revenue guidance, projecting results closer to the high end of its previous estimate.